Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143533 · ClinicalTrials.gov registry record · Phase 1
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00143533 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 20 participants.
The verdict
NCT00143533, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to estimate the maximum tolerated dose of irinotecan with the use of cefpodoxime for pediatric solid tumor patients.
Interventions
- DRUG Irinotecan, Cefpodoxime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143533
The ClinicalTrials.gov registry entry for NCT00143533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan, Cefpodoxime is the first listed.
NCT00143533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143533 about?
NCT00143533 is a clinical study titled "Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors". The primary purpose of this study is to estimate the maximum tolerated dose of irinotecan with the use of cefpodoxime for pediatric solid tumor patients.
What is the current status of trial NCT00143533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2003-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00143533?
The interventions under investigation include: Irinotecan, Cefpodoxime (DRUG).
Who is sponsoring clinical trial NCT00143533?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.